China Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . China Pharma Holdings
CPHI Stock  USD 1.64  0.07  4.09%   
China Pharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing China Pharma's valuation are provided below:
Gross Profit
-1.8 M
Profit Margin
(1.06)
Market Capitalization
5.3 M
Enterprise Value Revenue
1.9657
Revenue
4.3 M
We have found one hundred twenty available fundamental signals for China Pharma Holdings, which can be analyzed and compared to other ratios and to its rivals. Traders should compare all of China Pharma Holdings prevailing fundamentals against the fundamentals between 2010 and 2025 to make sure the company is sustainable this year.

China Pharma Total Revenue

4.3 Million

Check China Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among China Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.7 M, Interest Expense of 146.4 K or Selling General Administrative of 1.7 M, as well as many indicators such as Price To Sales Ratio of 8.54, Dividend Yield of 0.0 or PTB Ratio of 5.39. China financial statements analysis is a perfect complement when working with China Pharma Valuation or Volatility modules.
  
Build AI portfolio with China Stock
Check out the analysis of China Pharma Correlation against competitors.

China Pharma Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets14.1 M14.9 M63.8 M
Slightly volatile
Short and Long Term Debt Total3.4 M3.6 M8.5 M
Pretty Stable
Other Current Liabilities1.9 M1.8 M2.7 M
Very volatile
Total Current Liabilities9 M5 M10.2 M
Pretty Stable
Property Plant And Equipment Net4.3 M4.5 M15.2 M
Slightly volatile
Accounts Payable213.9 K225.1 K1.5 M
Slightly volatile
Cash595.5 K626.9 K2.7 M
Slightly volatile
Non Current Assets Total11 M11.6 M34.8 M
Slightly volatile
Cash And Short Term Investments595.5 K626.9 K2.7 M
Slightly volatile
Net Receivables267 K281.1 K14 M
Slightly volatile
Common Stock Total Equity37.5 K52.4 K42 K
Slightly volatile
Common Stock Shares Outstanding18.3 M17.5 M6.4 M
Slightly volatile
Liabilities And Stockholders Equity14.1 M14.9 M63.8 M
Slightly volatile
Non Current Liabilities Total3.5 M2.1 M4.9 M
Pretty Stable
Other Stockholder Equity22.4 M40.4 M25.7 M
Slightly volatile
Total Liabilities12.5 M7.1 M15.1 M
Pretty Stable
Property Plant And Equipment Gross19.3 M36.6 M23.6 M
Slightly volatile
Total Current Assets3.1 M3.3 M29 M
Slightly volatile
Short Term Debt2.1 M2.2 M4.4 M
Very volatile
Common Stock37.5 K32.6 K40.5 K
Pretty Stable
Current Deferred Revenue154.1 K162.2 K808.9 K
Slightly volatile
Inventory2.2 M2.3 M10.2 M
Slightly volatile
Intangible Assets3.5 M7.1 M2 M
Slightly volatile
Other Liabilities718.4 K948.1 K696.9 K
Slightly volatile
Property Plant Equipment17.9 M15.4 M17.8 M
Very volatile
Net Tangible Assets5 M5.3 M56.3 M
Slightly volatile
Capital Surpluse26 M28.1 M24.2 M
Slightly volatile
Long Term Debt Total3.5 M1.9 M5.1 M
Slightly volatile
Short and Long Term Debt4 M2.2 M7.6 M
Slightly volatile
Net Invested Capital17.5 M11.3 M35.2 M
Slightly volatile
Capital Stock34.1 K32.6 K42.6 K
Pretty Stable

China Pharma Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense146.4 K154.1 K436.2 K
Pretty Stable
Selling General Administrative1.7 M1.8 M2 M
Slightly volatile
Total Revenue4.3 M4.5 M19.2 M
Slightly volatile
Other Operating Expenses12 M9.1 M13.5 M
Slightly volatile
Selling And Marketing Expenses502.4 K528.8 K2.4 M
Slightly volatile
Cost Of Revenue6.2 M6.5 M15.6 M
Slightly volatile
Non Operating Income Net Other4.9 K5.1 K140 K
Pretty Stable
Interest Income6.3 K6.6 K410.6 K
Slightly volatile
Reconciled Depreciation2.3 M2.6 M3 M
Slightly volatile

China Pharma Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow2.8 M1.4 M3.1 M
Pretty Stable
Depreciation1.9 M2.6 M2.4 M
Slightly volatile
End Period Cash Flow595.5 K626.9 K2.7 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio8.548.984621 K
Slightly volatile
Dividend Yield0.01.0E-41.0E-4
Slightly volatile
Days Sales Outstanding19.6 M18.7 M2.4 M
Slightly volatile
Average Payables870.6 K916.5 K1.6 M
Slightly volatile
Stock Based Compensation To Revenue0.01060.01110.1556
Slightly volatile
Capex To Depreciation0.110.11141.6765
Slightly volatile
EV To Sales9.169.63921 K
Slightly volatile
Inventory Turnover0.00.01.6299
Very volatile
Days Of Inventory On Hand133.3 M127 M16.3 M
Slightly volatile
Payables Turnover15.1928.9410.9223
Slightly volatile
Sales General And Administrative To Revenue0.370.39410.2124
Very volatile
Average Inventory1.1 T1 T201.5 B
Slightly volatile
Research And Ddevelopement To Revenue0.04110.06270.034
Pretty Stable
Capex To Revenue0.120.06440.0985
Slightly volatile
Cash Per Share37.7 K35.9 K4.6 K
Slightly volatile
Payout Ratio0.050.05630.0614
Slightly volatile
Days Payables Outstanding11.9812.612368.554
Slightly volatile
Intangibles To Total Assets0.470.44440.0917
Slightly volatile
Current Ratio0.620.65182.3068
Slightly volatile
Receivables Turnover0.00.07.2773
Pretty Stable
Capex Per Share0.01590.01670.5503
Slightly volatile
Average Receivables710 K747.4 K12.3 M
Slightly volatile
Revenue Per Share0.250.25934.0995
Slightly volatile
Interest Debt Per Share0.20.21451.863
Pretty Stable
Debt To Assets0.360.23830.288
Very volatile
Graham Number25.924.2427.1262
Very volatile
Operating Cycle153 M145.7 M18.7 M
Slightly volatile
Days Of Payables Outstanding11.9812.612368.554
Slightly volatile
Dividend Payout Ratio0.050.05630.0614
Slightly volatile
Ebt Per Ebit1.261.03211.8049
Very volatile
Quick Ratio0.190.20021.4854
Slightly volatile
Net Income Per E B T3.112.961.4483
Slightly volatile
Cash Conversion Cycle153 M145.7 M18.7 M
Slightly volatile
Days Of Inventory Outstanding133.3 M127 M16.3 M
Slightly volatile
Days Of Sales Outstanding19.6 M18.7 M2.4 M
Slightly volatile
Fixed Asset Turnover0.950.99981.8461
Slightly volatile
Debt Ratio0.360.23830.288
Very volatile
Price Sales Ratio8.548.984621 K
Slightly volatile
Asset Turnover0.290.30060.32
Slightly volatile

China Pharma Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap24.5 M40.7 M22 M
Slightly volatile
Enterprise Value26.9 M43.7 M25.1 M
Slightly volatile

China Fundamental Market Drivers

Cash And Short Term Investments626.9 K

China Upcoming Events

12th of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About China Pharma Financial Statements

Investors use fundamental indicators, such as China Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although China Pharma's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue162.2 K154.1 K
Total Revenue4.5 M4.3 M
Cost Of Revenue6.5 M6.2 M
Stock Based Compensation To Revenue 0.01  0.01 
Sales General And Administrative To Revenue 0.39  0.37 
Research And Ddevelopement To Revenue 0.06  0.04 
Capex To Revenue 0.06  0.12 
Revenue Per Share 0.26  0.25 
Ebit Per Revenue(1.01)(1.06)

Currently Active Assets on Macroaxis

USOICredit Suisse X Links
ULTYTidal Trust II
CONYYieldMax N Option
BCATBlackRock Capital Allocation
PDIPimco Dynamic Income
When determining whether China Pharma Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of China Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of China Pharma Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on China Pharma Holdings Stock:
How To Invest In China
Details
Is China Stock a good investment?
Details
What is China Pharma's Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of China Pharma Correlation against competitors.
You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China Pharma. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.22)
Revenue Per Share
1.927
Quarterly Revenue Growth
(0.17)
Return On Assets
(0.18)
Return On Equity
(0.60)
The market value of China Pharma Holdings is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China Pharma's value that differs from its market value or its book value, called intrinsic value, which is China Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China Pharma's market value can be influenced by many factors that don't directly affect China Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between China Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if China Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY